During all 3 days:
one-to-one partnering and access to the DxPx Startup City.
Day 1
July 26th, 2022
9:30 am – 10:00 am
Opening speech
Welcome speech, DxPx US 2022.
10:30 am – 11:30 am
Panel discussion
European Startups: Undervalued opportunities for US Investors?!
12:00 pm – 1:00 pm
Panel discussion
The future of AI in health care.
2:00 pm – 3:00 pm
Panel discussion
Upscaling & manufacturing in Cell & Gene Therapies – Current challenges and solutions.
4:00 pm – 5:00 pm
Fireside chat
Establishing a new diagnostics gold standard in biomarkers. The importance of clinical involvement in launching novel diagnostics to change the standard of care.
Day 2
July 27th, 2022
10:00 am – 11:00 am
Panel discussion
Post-merger integrations in life sciences. The good, the bad, the ugly.
1:30 pm – 3:30 pm
42PLUS1 Satellite FINALS
Watch live pitches from 8 innovative startups from the diagnostics, digital health, precision medicine, & life science tools industries.
4:00 pm – 5:00 pm
Fireside chat
The current state and the future of single-cell tools and diagnostics.
7:00 pm – no end given
Reception
Join the legendary DxPx Reception! At the Rooftop Bar of Hiltons at McCormick Place.
Day 3
July 28th, 2022
9:30 am – 12:00 pm
Go beyond
Discover exciting startups at the DxPx Startup City.
Get to know ASCO Conquer Cancer; our charity partner.
Catch up on more meetings and make the best out of this opportunity.
Get to know the speakers joining DxPx US 2022
Kelly is a Managing Director at Probitas Partners responsible for research and he has 29 years of experience in private alternative fund investing and fundraising. Previously he was the Chief Operating Officer at Pacific Corporate Group, a consultant and fund-of-funds manager, focused on private equity partnership investment program globally. He has an MBA from the UCLA Anderson School of Management and a BA from Stanford University. He is currently a member of the Advisory Board at the Investment Management Due Diligence Association.
Sebastien Latapie has worked at the intersection of healthcare and technology for the last 10 years. He started his career in academia studying immunology and biochemistry at McGill, spent four years in consulting focused on healthcare, before joining Dynamk in 2019 where he focuses on partnering with startups enabling the future of life sciences.
Prenosis is a health tech innovator devoted to ushering in a new era of precision diagnostics in acute care using artificial intelligence. Its Immunix precision diagnostics platform leverages machine learning algorithms trained on deep biological data and broad clinical data to more holistically capture and illuminate the complex health states of patients. Its proprietary NOSIS dataset is the largest and fastest growing hybrid biomarker-clinical dataset for sepsis care. The Sepsis ImmunoScore diagnostic on the Immunix platform has the potential to save thousands of lives and billions of dollars in healthcare spending annually.
Richie Bavasso is a progressive life science entrepreneur and innovator driving new digital diagnostic and therapeutic initiatives. He is currently CEO and co-founder of nQ Medical Inc, a machine learning computational biomarker company leveraging personal devices to manage neurodegenerative diseases (AD, MCI, ALS, MS, PD). nQ builds powerful, AI solutions to support the continuum of neurological health. He serves as an international digital medicine consultant for German Enterprise. In this role, he supports these governments by advising and assisting life sciences, MedTech, and digital health start-ups in expansion into the US market.
Ye Bu has been with GE Healthcare since July 2021. Prior to GEHC, Ye serves as Managing Director at Guggenheim Securities with a focus on mergers and acquisitions in the medical technology sector. Before joining Guggenheim, Ye was a Director at Smith & Nephew for corporate development efforts in its Advanced Surgical Device business unit. Prior to that, Ye was a Vice President in the Healthcare investment banking group at Bank of America Merrill Lynch. Ye has worked on numerous merger and acquisition buy and sell-side mandates. Prior to Bank of America Merrill Lynch, she worked as a senior researcher at Dow Jones Newswires in China.
With 30+ years of healthcare experience she served in senior management roles for 10 diagnostic companies and has a key leadership in two company exits. A recognized leader in Cardiovascular Diagnostics. She is also the past Governor-appointed member of the Virginia Biotechnology Research Park Authority (9 yrs) and is currently on the Boards of Mid Atlantic-based BioHealth Innovation dedicated to translating science into market entry products.
His role is to investigate ways to convert challenges into business opportunities. and he helps drive innovation processes within Cytiva, Pall Biotechnology, and other Danaher operating companies. He is the Past-President of The Histochemical Society and serves on several advisory councils including the Leadership Advisory Council for the Advanced Regenerative Manufacturing Institute. He is the Co-Director of the upcoming Gordon Research Conference titled “Advanced Cell and Tissue Biomanufacturing” planned for June 2023.
Frank Peacock IV, MD, FACEP, FACC is a Professor of Emergency Medicine and Vice Chair of Research for the department of Emergency Medicine at the Baylor College of Medicine, in Houston, Texas. With over 600 peer reviewed publications, predominantly on heart failure and acute coronary syndromes, Dr. Peacock is also the co-editor of the textbooks Cardiac Emergencies, Short Stay Management of Heart Failure, Short Stay Management of Chest Pain, and Short Stay Management of Atrial Fibrillation.
A serial entrepreneur in IoT, medical devices, and wearables, Sridhar was a founder of Misfit, makers of elegant wearable products acquired by Fossil in 2015. Prior to Misfit, he founded AgaMatrix based on his Ph.D. research, a blood glucose monitoring company that made the world’s first iPhone-connected medical device. Sridhar holds more than 50 U.S. and international patents and received his Ph.D. from Cambridge University as a Marshall Scholar.
Ingo has over 25 years of experience building and leading high performance organizations in healthcare. He was President and CEO of Mesa Biotech, a rapid-PCR technology and testing company in infectious disease. Mesa was acquired by Thermo Fisher for up to $550M in February 2021. He spent the last two decades building global business, holding senior leadership positions at Navican Genomics, GenMark Diagnostics, Gen-Probe, Roche and Ventana Medical Systems.
.
Adriana supports the Research team at Rock Health as an associate. Previously, Adriana worked as a researcher and strategist for health-centered organizations including C-TAC (the Coalition to Transform Advanced Care) and the Massachusetts Office of Elder Affairs. Adriana earned her bachelor’s degree in business from Fordham University and her master’s degree in health equity and aging studies from Harvard University. Adriana has published research and led projects related to technology ethics, community-based digital health programs, and virtual care services for Medicare populations.
25 years experience in life science research and biotechnology tools industry. 10+ years experience in biotech start-up, consulting and corporate settings in life science business development, sales and marketing and strategy development. Advisory services to large corporate entities with interest in biotechnology tools and advisory to corporate boards and investment professionals regarding the biotechnology tools market and opportunities. Additional focus on non-US companies requiring perspective on US market for investment capital, licensing, and corporate partnership.
Julianne is an experienced early-stage healthcare investor. Currently, she leads health ventures at Plug and Play where she's made over 16 investments and worked with over 24 global corporations, covering pharma, payors, providers, consumer, and government. She previously worked on strategic projects and business development for a global nonprofit and started her career at a biotech venture fund. 
Welcome to DxPx! It is our fourth year holding the DxPx Conference, and we are happy to share this success with all of you.
This year, the whole DxPx team is excited to reach another milestone which is being in person at AACC Clinical Lab Expo, in McCormick Place, Chicago for the first time. Being in the flesh in the US this year certainly paves the way for more startups, growth companies, industry leaders, and investors to join the partnering conference and develop valuable business connections.
Moderator
.
John leads BGL’s advisory activities in the Healthcare & Life Sciences investment banking group, which comprises both corporate investment banking and real estate capital markets capabilities. Together with his team, John maintains an ongoing coverage effort with broad activity across several sectors, including health facilities, physician services, and ancillary providers; diagnostics and research tools; medical device and products; and select healthcare technology verticals, including payor services, data analytics, and clinical automation.
Moderator
Michele Colucci, Founder + Managing Partner, is a lawyer, investor, serial entrepreneur, and philanthropist. Currently, Michele serves on the Boards of Directors Nephrosant, Optina Diagnostics, Prime Genomics, and Delphi Diagnostics and previously the Global Indemnity Group. She is also an Advisor to eHealth Analytics and Quantellia (a platform powering decision-based analytics through artificial intelligence). She has blogged for the Huffington on female entrepreneurship and is an award-winning expert on E-Local. She served as a guest lecturer and mentor at Stanford University’s School of Engineering focused on Global Marketing and Entrepreneurship and has lectured at USF in marketing and at USC’s Gould School of Law. 
Moderator
Dr. Volker Gatterdam studied chemistry in the beautiful city of Marburg, Germany. He holds a doctoral degree with summa cum laude in biochemistry from the University of Frankfurt where he laid a solid foundation for his scientific interests. His work is focused on the chemical modifications of surfaces for the design and fabrication of biosensors. His interest in the fascinating technology of focal molographystarted during his in Prof. Janos at ETH Zurich. His continuous passion for the technology led him to be one of the co-founders of lino Biotech. Dr. Gatterdam´s combined focal molography and business knowhow strengthens lino´s project and quality management.
Moderator
Angus McQuilken has 29 years of experience in leadership positions in communications, marketing, business development and public affairs. After nine years as the state‘s lead communicator in life sciences, he is now leading life sciences practice growth initiatives for McDermott Will & Emery.
Moderator
He is a healthcare and life sciences investment banker with a background of over 20 years in all aspects of operations planning, financial management, and general management for Diagnostics, Research Tools, CRO, CDMO, and Medical Devices companies. He has a very strong international business background that includes both U.S. and trans-European experience.
Provides international tax & legal advice for public or private multi-national clients, related to tax-efficient planning, cross-border transfers, internal reorganizations, and business transitions. His practice focuses on growing, acquiring or exiting multi-country businesses, including assessing exposures, recommending tax-efficient strategies, and executing the necessary legal steps. He is known to consistently identify tax-saving opportunities and provide valuable strategic planning.
Panels & Sessions
European Startups: Undervalued opportunities for US Investors?!
July 26th, 2022 | 10:30 am - 11:30 am
Cross-border investments from US-based VCs in European startups have continuously increased over the past years. In 2021, every 5th European deal had at least one U.S. investor on board, up from 17% in 2020 and 15% in 2019. Investors and entrepreneurs on this panel will discuss the unique challenges and opportunities that result from such cross-board deals and provide tips on how to best find and attract the right partners in oversea.
Speakers: Kelly De Ponte, Sebastien Latapie, William (Bill) Hyun
Moderator: Angus McQuilken
The future of AI in health care.
July 26th, 2022 | 12:00 pm - 1:00 pm
Almost everyone considers AI applications in health care to become a game changer with major benefits on patient treatments and cost structures. Yet, regulatory approval and education of users such as physicians to trust algorithms remain challenging. In this panel we review how large-cap and smaller startups successfully overcame some of these hurdles and discuss what is needed over the next 5 years to realize more of the value that AI can offer to the health care system.
Speakers: Bobby Reddy, John Chen, Richie Bavasso, Ye Bu, Julianne Roseman
Moderator: Michele Colucci
Upscaling & manufacturing in Cell & Gene Therapies Current challenges and solutions.
July 26th, 2022 | 2:00 pm - 3:00 pm
Cell & Gene Therapies are considered to be the next big wave in medicine. Unlike classical pharmaceuticals, these therapies heavily depend on the quality of the manufacturing process. In addition, the short shelf life of the final products makes collecting data on safety and potency a time-critical challenge. Together with industry leaders and innovative life science tools companies, we will discuss new solutions and open gaps that need to be filled to make CGTs broadly accessible.
Speakers: Bryan Poltilove
Moderator: Volker Gatterdam
Establishing a new diagnostics gold standard in biomarkers.
July 26th, 2022 | 4:00 pm - 5:00 pm
The importance of clinical involvement in launching novel diagnostics to change the standard of care. Novel diagnostic methods have the potential to change the standard of care in healthcare. In this fireside chat we review how Cardiac troponin (cTn) has become an essential part of diagnosing myocardial infarction (MI) since testing for it was introduced in the 1990s and what the lessons are for launching similar diagnostic methods.
Speakers: Frank Peacock, Donna Edmonds
Moderator: Christoph Brandenberger
Post-merger integrations in life sciences. The good, the bad, the ugly.
July 27th, 2022 | 10:00 am - 11:00 am
Many transactions in the diagnostics & tools space are structured with a significant part of the compensation being linked to future milestones. Yet, with more than half of mergers and acquisitions failing or underperforming, it is important to learn how to increase chances for success. Bringing together two organization, each with its own processes, culture, and management, is complex and requires full attention before and after the transaction. We learn from buyers, and entrepreneurs what to look out for and what mistakes to avoid.
Speakers: Sridhar Iyengar, Ingo Chakravarty,
Moderator: Mike Hardgrove
Digital health funding: Staying the course in choppy waters.
July 27th, 2022 | 12:00 pm - 1:00 pm
How can an organization know that short-term price increases are fair and in line with expectations? How can companies prepare to deal with the long-term consequences of inflationary markets? No one can perfectly predict the next set of inflationary pressures, but it’s reasonable to assume that they’ll return eventually. Leaders can prepare now to minimize the impact when that day arrives.
Speakers: Adriana Krasniansky
Moderator: Matthias Breugelmans
42PLUS1 Pitch Award.
July 27th, 2022 | 1:30 pm - 3:30 pm
42PLUS1 is one of the highest prized pitch awards and part of the DxPx Conference. Supporting startups and growth companies is what drives DxPx – for that reason 42PLUS1 offers $2,000,000 for the finalists of the grand finale, in the form of convertible loans. The grand finale will take place alongside DxPx EU in November 2022, while the Satellite 42PLUS1 Pitch Award, taking place at DxPx US, provides the winner with a spot to pitch straight at the grand finale! With a huge audience of international investors and industry executives, participating startups have the chance to make a real difference and accelerate their business.
The current state and the future of single cell tools and diagnostics.
July 27th, 2022 | 4:00 pm - 5:00 pm
Single-cell molecular tools have been developed at an incredible pace over the last five years as sequencing costs continue to drop and numerous molecular assays have been coupled to sequencing readouts. This rapid period of technological development has facilitated the delineation of individual molecular characteristics including the genome, transcriptome, epigenome, and proteome of individual cells, leading to an unprecedented resolution of the molecular networks governing complex biological systems.
Speakers: Rodney Turner
Moderator: John Riddle
Go beyond.
July 27th, 2022 | 9:00 am - 12:00 pm
Take your chance to learn about new technologies and investment opportunities from around the world and visit the DxPx Startup City. All while enjoying some coffee and bringing some color in your life.
DxPx US 2022 is
DxPx US 2022 Floor Plan
DxPx Us 2022 is located in the heart of the AACC Clinical Lab Expo, at the McCormick Place in Chicago, USA.
The AACC Clinical Lab Expo has 700+ exhibitors, 200+ product categories, and live demos. To add, we (the DxPx team) are building a Startup City at the American Association for Clinical Chemistry (AACC)!
Don't miss these opportunities.
✅ Explore Startup City and discover innovative products and services
✅ Experience one-to-one partnering and networking
✅ Learn from the riveting fireside chats and panel discussions
✅ Discover 700+ exhibitors and 200+ product categories at the AACC Clinical Lab Expo
✅ Watch and listen to 42PLUS1 Pitch Award live!
✅ End your day in our legendary rooftop reception and see the amazing skyline of Chicago at VU Rooftop Bar, Hiltons at McCormick Place
3 Days in Person: July 26th to 28th, 2022, AACC Clinical Lab Expo, McCormick Place, Chicago
2 Weeks Digital Partnering: July 14th – 25th, 2022
Startup City
On the way to the US to build a Startup City at the 2022 AACC Clinical Lab Expo in McCormick Place, Chicago!
We are excited to share this milestone with startups, growth companies, investors, and executives focusing on Diagnostics, Digital Health, Precision Medicine, and Life Science tools.
Explore countless possibilities when you join the three days in person partnering from July 26th to 28th:
☑️ Promote your company to industry executives and showcase products at your (Startup City) booth
☑️ Connect with active family offices, venture capitals, private equity, strategic investors who will be visiting your booth
☑️ Experience and learn from the panel discussions, fireside chats, and sessions at the DxPx
DxPx Partnering Area
With the gaining importance of diagnostics, digital health, precision medicine and life science tools there is a need for a dedicated platform to bring together the relevant stakeholders and further drive our industries.
We are inviting all stakeholders focusing on the industries above to come and join us in the Startup City at the DxPx Conference. Meet your next collaborator through this partnering event and gain access to one-to-one meetings to discuss financing, co-development, licensing, and M&A opportunities.
Sponsors' Area
DxPx Conference has been growing and expanding because of the support of our partners and sponsors. We are happy about building new partnerships but we are even happier when we maintain partnerships over the years!
Our sponsors and knowledge partners help drive our industries forward and we are happy to enable them to share their vision with everyone attending the DxPx Conference.
Working Area
While networking and partnering are the heart of DxPx we understand that this is a fast-paced and ever online world.
Surpassing itself, the conference is in a hybrid format with a digital partnering that takes place before the in person event, enabling partnering opportunities for every participant, on- or off-site. Our working area might just be what you need to comfortably catch up on any online meetings you can pre-schedule via our digital partnering platform!
Our partnering area is ~20.000ft2/2.000m2 making it possible to mount all exhibition, networking, startup city areas & panel discussions for our participants, while still providing our participants with a lounge and a dedicated working area!
Panels & Sessions' Venue
The whole DxPx team is excited to welcome you to the conference. Meet relevant investors, industry leaders, startups, growth companies, and accelerators from 30+ countries!
Receive insights and learnings from the riveting panel discussions and fireside chats brought to you by renowned speakers from the industry.
Did you know that the 42PLUS1 Pitch Award's finals will be taking place in this very venue! Watch the 8 finalists pitch live on stage for a shot a $2,000,000 in convertible loans!
Date & Location: July 26th - 28th, 2022
at AACC Clinical Lab Expo, McCormick Place, Chicago
